Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma
about
Particle therapy for non-small cell lung tumors: where do we stand? A systematic review of the literatureFeasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRTA phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapyDefinitive radiotherapy alone over 60 Gy for patients unfit for combined treatment to stage II-III non-small cell lung cancer: retrospective analysis.DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer.Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer.Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB-IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities.Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy.Hyperfractionated and accelerated radiotherapy in non-small cell lung cancer.Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer.Correlation analysis of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside uptake distributions in lung tumours during radiation therapy.Evolution of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside PET uptake distributions in lung tumours during radiation therapy.PET in the management of locally advanced and metastatic NSCLC.What is changing in radiotherapy for the treatment of locally advanced nonsmall cell lung cancer patients? A review.Synergistic effect of phenformin in non-small cell lung cancer (NSCLC) ionizing radiation treatment.A geometric atlas to predict lung tumor shrinkage for radiotherapy treatment planning.From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?Effect of variations in atelectasis on tumor displacement during radiation therapy for locally advanced lung cancer.Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer : A retrospective study of elderly patients with stage III disease.GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer.Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up.Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer.The value of nodal information in predicting lung cancer relapse using 4DPET/4DCT.Tumour auto-contouring on 2d cine MRI for locally advanced lung cancer: A comparative study.Early PET/CT scans for assessing treatment responses of non-small cell lung cancer for SBRT boost: what to do with scans from multiple scanners.Treating locally advanced lung cancer with a 1.5T MR-Linac - Effects of the magnetic field and irradiation geometry on conventionally fractionated and isotoxic dose-escalated radiotherapy.The development of a 4D treatment planning methodology to simulate the tracking of central lung tumors in an MRI-linac.Local failure after radical radiotherapy of non-small cell lung cancer in relation to the planning FDG-PET/CT.Clinical use of iterative 4D-cone beam computed tomography reconstructions to investigate respiratory tumor motion in lung cancer patients.Dosimetric impact of respiratory motion, interfraction baseline shifts, and anatomical changes in radiotherapy of non-small cell lung cancer.Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.Resolution of atelectasis during radiochemotherapy of lung cancer with serious implications for further treatment. A case report.Advances in radiation therapy for thoracic malignancies
P2860
Q27023426-7C2F508D-6639-4E6E-A025-6308155AEBF8Q29248450-79547C81-D66B-49AD-9FCA-E491698E3F33Q34041735-580BC951-0B10-45E4-BA8A-E07A21286EEBQ36131115-5D995F72-6467-4380-818B-A1B6E142FBA0Q36344205-9F4619F7-6070-4ADD-B930-F18B5FD0C3B3Q36710620-FF9FE826-A015-4ED1-AE19-8880D31C1263Q36869865-5E750A95-CBD9-4233-910D-C52ECC55AED2Q37037949-CBD011A3-7EBF-4EB6-8E68-3D48C705057EQ37516506-8772133A-B5B3-4036-BAAA-8299D95C77EEQ37567299-76F9DF73-830C-4C93-A24F-9DE02D402650Q37581168-02E43D54-0F28-4FC5-A264-5140F578E485Q37670429-AE3A7F71-52E1-4235-976F-FB5433D7CF33Q38350598-165827AC-9AB4-4543-891B-5435D8507CDAQ38400856-60229DD3-21AE-47BE-B6BA-5DE2A090875FQ38401906-E511296F-048E-4AD1-B869-D82761FBE2AAQ38444980-9E6267CE-E8ED-452E-9E04-D33097E2B1A0Q38711723-D9EA28CF-09DC-4E1B-B8BC-396565449DCAQ38948150-3AFEE668-A284-43E7-B936-E2210EE8D462Q39029314-50A8F4BB-C15D-4EB3-AFBE-A7481F5EA0D1Q39041541-E272C71D-F21F-4CBA-B1A7-CC93C02AC705Q39456195-678447CB-2855-49DE-BE91-5CD72214AF00Q40346974-8E98751C-18E6-419B-87DB-344C51ED9DDBQ40951849-E3973B8F-8174-4748-A11E-2430A8B6EF8EQ41455781-91016DE2-FE2C-4686-B713-C58B799AEEB6Q41613080-85FDAEE2-BCA0-4EB5-B03E-DCFF682C4F0EQ44174829-D2837675-126B-46C0-BDCA-E28D0D023DBDQ45953810-DA6DD36F-BED7-46F8-93F6-FC824F40300AQ47118653-D7C2D1AC-7DBD-439C-90E6-25B454AFFD34Q47132869-1EBE3FFE-EDF3-419F-ACD5-F073E1185611Q47163187-365C3F29-3A20-462E-AAAD-512D4093169DQ47384096-5C44D7DF-DCD9-4E36-9F5B-F701EA3CEA9CQ48181398-6A6B5ABA-D404-4178-BA4E-25425F9A364DQ51074843-520840F0-EF5B-43D3-B534-466D64263A11Q51180183-BDEA59CB-B515-4643-810E-A624A7A3D10EQ52878867-20D42743-27B8-413F-B198-936FF1206DC2Q55113219-785F4F94-4C30-44A4-B232-639BB69476F5Q58804844-DE992743-8BF8-4158-80BE-94FC454ECFDC
P2860
Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Defining local-regional contro ...... non-small cell lung carcinoma
@ast
Defining local-regional contro ...... non-small cell lung carcinoma
@en
type
label
Defining local-regional contro ...... non-small cell lung carcinoma
@ast
Defining local-regional contro ...... non-small cell lung carcinoma
@en
prefLabel
Defining local-regional contro ...... non-small cell lung carcinoma
@ast
Defining local-regional contro ...... non-small cell lung carcinoma
@en
P2093
P2860
P1476
Defining local-regional contro ...... non-small cell lung carcinoma
@en
P2093
Benjamin Movsas
J Effrey Bradley
Jennifer Moughan
Kathy Albain
Rebecca Paulus
Walter J Curran
William T Sause
P2860
P304
P356
10.1097/JTO.0B013E3182429682
P577
2012-04-01T00:00:00Z